Nucryst shakes up management, sidelines program

Nucryst Pharmaceuticals has shaken up its management and shelved one of its development programs. Nucryst announced that it had "discontinued the development of, and out-licensing initiatives for, the current formulation of NPI 32101 silver to treat inflammatory bowel disease."

David C. McDowell, vice president operations, adds R&D responsibilities to his job description and Edward Gaj has been named vice president marketing. Katherine J. Turner, PhD, vice president research and development, is leaving to explore outside opportunities.

- read Nucryst's release

Suggested Articles

The CTAD presentation cleared up some questions about the dataset without delivering a telling blow for either side of the debate.

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.